Alyeska Investment Group
AMLX icon

Alyeska Investment Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Alyeska Investment Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-750,412
Closed -$2.66M – 553
2025
Q1 		$2.66M Sell
750,412
-73,008
-9% -$260K 0.01% 404
2024
Q4 		$3.11M Sell
823,420
-1,200,000
-59% -$5.65M 0.01% 438
2024
Q3 		$6.56M Buy
2,023,420
+200,000
+11% +$450K 0.03% 327
2024
Q2 		$3.46M Buy
1,823,420
+814,813
+81% +$1.58M 0.02% 371
2024
Q1 		$2.86M Buy
+1,008,607
New +$13.2M 0.02% 360
2023
Q4 		– Sell
-120,157
Closed -$2.2M – 519
2023
Q3 		$2.2M Sell
120,157
-200,000
-62% -$4.23M 0.01% 384
2023
Q2 		$6.91M Buy
320,157
+68,750
+27% +$1.86M 0.05% 307
2023
Q1 		$7.38M Buy
251,407
+201,407
+403% +$7M 0.06% 272
2022
Q4 		$1.85M Buy
+50,000
New +$1.77M 0.02% 326

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Alyeska Investment Group's AMLX Position: Q2 2025 in Review

Alyeska Investment Group sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 750,412 shares — an estimated $2.66M sold.

Alyeska Investment Group first reported a position in AMLX in Q4 2022 and held it in 9 quarters. The position peaked at $7.38M in Q1 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Alyeska Investment Group reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 750,412 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $2.66M.
  • Alyeska Investment Group first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Alyeska Investment Group's Amylyx Pharmaceuticals position peaked at $7.38M in Q1 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.